WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.
The deal grants Ona Therapeutics rights to develop the ADC targeting a single undisclosed target.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It includes an upfront payment from Ona Therapeutics to WuXi XDC, along with additional payments tied to development, regulatory, and sales milestones.
WuXi XDC will also be eligible for tiered royalties on net sales if the ADC product reaches commercialisation.
The company will also deliver chemistry, manufacturing and controls development.
It will also provide manufacturing support through its integrated ADC contract research, development, and manufacturing platform.
This collaboration marks the second time that Ona Therapeutics and WuXi XDC have worked together in the ADC sector.
The companies previously entered a partnership in 2024, in which Ona Therapeutics licensed additional technologies for its ADC pipeline.
WuXi XDC CEO Jimmy Li said: “We are truly honoured to join forces once again with Ona Therapeutics. As an innovative biotech company focused on first-in-class targets, Ona’s deep insights into novel targets are highly complementary to WuXi XDC’s leading ADC technology platforms.
“With its hydrophilic linker delivering significantly enhanced ADC stability, the WuXiTecan 2 platform has completed two out-licensing deals within just six months. This collaboration not only further validates the value of our WuXiTecan 2 platform but also reaffirms WuXi XDC’s commitment to empowering innovative biotech companies worldwide.
“Through our integrated, end-to-end CRDMO platform, we look forward to fully supporting Ona Therapeutics in accelerating this first-in-class ADC candidate into the clinic, bringing new treatment options to patients.”
Ona Therapeutics is engaged in developing ADCs for cancers that are resistant to treatment by utilising a discovery platform focused on new tumour-specific antigens and epitopes.
ADC content on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Syngene. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
